748 related articles for article (PubMed ID: 32269342)
1. Integrating genomic features for non-invasive early lung cancer detection.
Chabon JJ; Hamilton EG; Kurtz DM; Esfahani MS; Moding EJ; Stehr H; Schroers-Martin J; Nabet BY; Chen B; Chaudhuri AA; Liu CL; Hui AB; Jin MC; Azad TD; Almanza D; Jeon YJ; Nesselbush MC; Co Ting Keh L; Bonilla RF; Yoo CH; Ko RB; Chen EL; Merriott DJ; Massion PP; Mansfield AS; Jen J; Ren HZ; Lin SH; Costantino CL; Burr R; Tibshirani R; Gambhir SS; Berry GJ; Jensen KC; West RB; Neal JW; Wakelee HA; Loo BW; Kunder CA; Leung AN; Lui NS; Berry MF; Shrager JB; Nair VS; Haber DA; Sequist LV; Alizadeh AA; Diehn M
Nature; 2020 Apr; 580(7802):245-251. PubMed ID: 32269342
[TBL] [Abstract][Full Text] [Related]
2. Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning.
Liang N; Li B; Jia Z; Wang C; Wu P; Zheng T; Wang Y; Qiu F; Wu Y; Su J; Xu J; Xu F; Chu H; Fang S; Yang X; Wu C; Cao Z; Cao L; Bing Z; Liu H; Li L; Huang C; Qin Y; Cui Y; Han-Zhang H; Xiang J; Liu H; Guo X; Li S; Zhao H; Zhang Z
Nat Biomed Eng; 2021 Jun; 5(6):586-599. PubMed ID: 34131323
[TBL] [Abstract][Full Text] [Related]
3. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR
Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595
[TBL] [Abstract][Full Text] [Related]
4. Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA.
Peng M; Xie Y; Li X; Qian Y; Tu X; Yao X; Cheng F; Xu F; Kong D; He B; Liu C; Cao F; Yang H; Yu F; Xu C; Tian G
J Med Genet; 2019 Oct; 56(10):647-653. PubMed ID: 30981987
[TBL] [Abstract][Full Text] [Related]
5. Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors.
Lenaerts L; Vandenberghe P; Brison N; Che H; Neofytou M; Verheecke M; Leemans L; Maggen C; Dewaele B; Dehaspe L; Vanderschueren S; Dierickx D; Vandecaveye V; Amant F; Vermeesch JR
Ann Oncol; 2019 Jan; 30(1):85-95. PubMed ID: 30371735
[TBL] [Abstract][Full Text] [Related]
6. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
8. Unbiased Detection of Somatic Copy Number Aberrations in cfDNA of Lung Cancer Cases and High-Risk Controls with Low Coverage Whole Genome Sequencing.
Taylor F; Bradford J; Woll PJ; Teare D; Cox A
Adv Exp Med Biol; 2016; 924():29-32. PubMed ID: 27753014
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
10. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
[TBL] [Abstract][Full Text] [Related]
11. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
12. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA).
Liang W; Zhao Y; Huang W; Gao Y; Xu W; Tao J; Yang M; Li L; Ping W; Shen H; Fu X; Chen Z; Laird PW; Cai X; Fan JB; He J
Theranostics; 2019; 9(7):2056-2070. PubMed ID: 31037156
[No Abstract] [Full Text] [Related]
14. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
15. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
[TBL] [Abstract][Full Text] [Related]
17. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
18. Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer.
Fernandez-Cuesta L; Perdomo S; Avogbe PH; Leblay N; Delhomme TM; Gaborieau V; Abedi-Ardekani B; Chanudet E; Olivier M; Zaridze D; Mukeria A; Vilensky M; Holcatova I; Polesel J; Simonato L; Canova C; Lagiou P; Brambilla C; Brambilla E; Byrnes G; Scelo G; Le Calvez-Kelm F; Foll M; McKay JD; Brennan P
EBioMedicine; 2016 Aug; 10():117-23. PubMed ID: 27377626
[TBL] [Abstract][Full Text] [Related]
19. Early detection of pre-malignant lesions in a KRAS
Rakhit CP; Trigg RM; Le Quesne J; Kelly M; Shaw JA; Pritchard C; Martins LM
Dis Model Mech; 2019 Feb; 12(2):. PubMed ID: 30760495
[TBL] [Abstract][Full Text] [Related]
20. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges.
García-Pardo M; Makarem M; Li JJN; Kelly D; Leighl NB
Br J Cancer; 2022 Sep; 127(4):592-602. PubMed ID: 35347327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
